drugset / Trial / NCT00324077
Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out whether adding a new drug, dasatinib, to imatinib is safe, and whether the combination of the two drugs will help decrease the number of cells that contain the Philadelphia chromosome.
Timeline
- Start
- 2006-08
- Primary completion
- 2007-02
- Completion
- —
Outcome
Outcome not reported
Stopped (Enrollment): “Insufficient Enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dasatinib anhydrous | Small molecule | — | — |
| Background | Imatinib | Small molecule | — | — |